Osteoporosis drugs 'bundle' before breast cancer

An important test to assess whether a regular bone tightener may help prevent breast cancer from recurring.

The results show that this drug has no benefit for most patients.

Image for illustrative purposes. (Internet source)

Doctors participating in the experiment on December 9 said the five-year study was conducted for 3,360 women with end-stage breast cancer who had had surgery.

The study piloted a number of patients, using osteoporosis medicine Zometa, a drug called zoledronic acid, accompanied by standard therapy.

The hope of this study is that drugs can prevent cancer from recurring. However, the American Association for Cancer Research (AACR) said the drug had no effect on the " survival rate " for all patients.

At the conference in San Antonio, Texas, Professor Robert Coleman of the Department of Oncology at the University of Sheffield in the UK said: ' For the larger population, we do not see any difference '. However, he added that there is a slight difference for age groups, especially older patients who respond better to drugs.

However, young patients do not get any benefit from taking the drug if not worse.

Zoledronic acid used to treat blood calcium levels occurs simultaneously with cancer and also helps prevent fractures in cancer patients.